Novo Nordisk (NVO) ended a five-day losing streak on Thursday after Kepler Cheuvreux, a long-time skeptic of the Danish biotech, finally issued a bullish rating on the maker of hugely popular obesity/ diabetes drugs, Ozempic and Wegovy.

Nine years after